PACIRA BIOSCIENCES INC
PCRXNASDAQTrading Snapshot
- Day Range
- $25.40 – $25.80
- 52-Week Range
- $18.80 – $27.66
- Volume
- $1.93B
- Avg Volume
- $2.27B
- Shares Outstanding
- 39.4M
- Next Earnings
- Nov 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $726M
- Last Q Revenue
- $192M
- P/E Ratio
- 69.5
- P/S Ratio
- 1.4x
- EPS (TTM)
- $0.35
- Dividend Yield
- —
- Dilution (1yr)
- −12.3%
Why Investors Own PCRX
- ✓High-growth profile — revenue up +4.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PACIRA BIOSCIENCES INC
PCRX
StockOtter · stockotter.spaceAbout PACIRA BIOSCIENCES INC
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
240,006 Shares in Pacira BioSciences, Inc. $PCRX Acquired by Bank of America Corp DE
Bank of America Corp DE bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commis
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announc
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
Pacira (PCRX) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.74 per share a year ago.